1
|
Drygalski K, Fereniec E, Zalewska A, Krętowski A, Żendzian-Piotrowska M, Maciejczyk M. Phloroglucinol prevents albumin glycation as well as diminishes ROS production, glycooxidative damage, nitrosative stress and inflammation in hepatocytes treated with high glucose. Biomed Pharmacother 2021; 142:111958. [PMID: 34333287 DOI: 10.1016/j.biopha.2021.111958] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 07/21/2021] [Accepted: 07/22/2021] [Indexed: 12/18/2022] Open
Abstract
The treatment of diabetes mellitus aftermaths became one of medicine's most significant therapeutical and financial issues in the XXI century. Most of which are related to protein glycation and oxidative stress caused by long lasting periods of hyperglycemia. Thus, even within a venerable one, searching for new drugs, displaying anti-glycation and anti-oxidative properties seem useful as an additive therapy of diabetes. In this paper, we assessed the anti-glycating properties of phloroglucinol, a drug discovered in the XIX century and still used in many countries for its antispasmodic action. Herewith, we present its effect on protein glycation, glycoxidation, and oxidative damage in an albumin glycation/oxidation model and HepG2 cells treated with high glucose concentrations. The phloroglucinol showed the strongest and the widest protective effect within all analyzed antiglycating (aminoguanidine, pioglitazone) and anti-oxidative (vitamin C, GSH) agents. To the very best of our knowledge, this is the first study showing the properties of phloroglucinol in vitro what once is proven in other models might deepen its clinical applications.
Collapse
Affiliation(s)
- Krzysztof Drygalski
- Clinical Research Center, Medical University of Bialystok, Poland; Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Poland.
| | | | - Anna Zalewska
- Experimental Dentistry Laboratory, Medical University of Bialystok, Poland
| | - Adam Krętowski
- Clinical Research Center, Medical University of Bialystok, Poland; Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Poland
| | | | - Mateusz Maciejczyk
- Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, Poland.
| |
Collapse
|
2
|
Ji RC. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett 2013; 346:6-16. [PMID: 24333723 DOI: 10.1016/j.canlet.2013.12.001] [Citation(s) in RCA: 117] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Revised: 11/28/2013] [Accepted: 12/04/2013] [Indexed: 12/29/2022]
Abstract
Hypoxia and lymphangiogenesis are closely related processes that play a pivotal role in tumor invasion and metastasis. Intratumoral hypoxia is exacerbated as a result of oxygen consumption by rapidly proliferating tumor cells, insufficient blood supply and poor lymph drainage. Hypoxia induces functional responses in lymphatic endothelial cells (LECs), including cell proliferation and migration. Multiple factors (e.g., ET-1, AP-1, C/EBP-δ, EGR-1, NF-κB, and MIF) are involved in the events of hypoxia-induced lymphangiogenesis. Among them, HIF-1α is known to be the master regulator of cellular oxygen homeostasis, mediating transcriptional activation of lymphangiogenesis via regulation of signaling cascades like VEGF-A/-C/-D, TGF-β and Prox-1 in experimental and human tumors. Although the underlying molecular mechanisms remain incompletely elucidated, the investigation of lymphangiogenesis in hypoxic conditions may provide insight into potential therapeutic targets for lymphatic metastasis.
Collapse
Affiliation(s)
- Rui-Cheng Ji
- Department of Human Anatomy, Oita University Faculty of Medicine, Oita, Japan.
| |
Collapse
|
4
|
Spinella F, Caprara V, Garrafa E, Di Castro V, Rosanò L, Natali PG, Bagnato A. Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cellsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research. Can J Physiol Pharmacol 2010; 88:782-7. [DOI: 10.1139/y10-050] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The molecular mechanisms involved in lymphangiogenesis were unknown until recently. We previously demonstrated that the endothelin-1 (ET-1) axis stimulates lymphatic endothelial cells (LEC) and lymphatic vessels to grow and invade. Here we further investigated the effect of ET-1 on lymphatic vessels and evaluated whether ET-1 actions result in the functional activation of lymphangiogenesis. Using highly purified human LEC, characterized for the expression of ET-1 axis members by quantitative real-time PCR, we found that the endothelin B receptor (ETB), upon activation by ET-1, induced matrix-metalloproteinase activation, demonstrating that ET-1 influenced the activity of the proteolytic enzymes required for LEC invasion. Functional assays performed by using intradermal lymphangiography demonstrated that ET-1 promoted the formation of lymphatic vessels and that these vessels were capable of lymphatic flow. ETB blockade with the specific antagonist BQ788 inhibited matrix-metalloproteinase activation and dye transport within the lymphatic vessels, demonstrating that ETB is involved in the regulation of the growth of and in the formation of functional vessels upon activation by ET-1. Our results suggest that ET-1 is a lymphangiogenic mediator and that targeting pharmacologically ETB may be therapeutically exploited in a variety of diseases, including cancer.
Collapse
Affiliation(s)
- Francesca Spinella
- Molecular Pathology Laboratory, Regina Elena Cancer Institute, 00144 Rome, Italy
- Microbiology Section, Department of Experimental Medicine, University of Brescia, 25121 Brescia, Italy
| | - Valentina Caprara
- Molecular Pathology Laboratory, Regina Elena Cancer Institute, 00144 Rome, Italy
- Microbiology Section, Department of Experimental Medicine, University of Brescia, 25121 Brescia, Italy
| | - Emirena Garrafa
- Molecular Pathology Laboratory, Regina Elena Cancer Institute, 00144 Rome, Italy
- Microbiology Section, Department of Experimental Medicine, University of Brescia, 25121 Brescia, Italy
| | - Valeriana Di Castro
- Molecular Pathology Laboratory, Regina Elena Cancer Institute, 00144 Rome, Italy
- Microbiology Section, Department of Experimental Medicine, University of Brescia, 25121 Brescia, Italy
| | - Laura Rosanò
- Molecular Pathology Laboratory, Regina Elena Cancer Institute, 00144 Rome, Italy
- Microbiology Section, Department of Experimental Medicine, University of Brescia, 25121 Brescia, Italy
| | - Pier Giorgio Natali
- Molecular Pathology Laboratory, Regina Elena Cancer Institute, 00144 Rome, Italy
- Microbiology Section, Department of Experimental Medicine, University of Brescia, 25121 Brescia, Italy
| | - Anna Bagnato
- Molecular Pathology Laboratory, Regina Elena Cancer Institute, 00144 Rome, Italy
- Microbiology Section, Department of Experimental Medicine, University of Brescia, 25121 Brescia, Italy
| |
Collapse
|
6
|
Azzali G. Transendothelial transport and migration in vessels of the apparatus lymphaticus periphericus absorbens (ALPA). INTERNATIONAL REVIEW OF CYTOLOGY 2004; 230:41-87. [PMID: 14692681 DOI: 10.1016/s0074-7696(03)30002-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The vessel of the apparatus lymphaticus periphericus absorbens (ALPA) represents the sector with high absorption capacity of the canalization of the lymphatic vascular system. It plays a basic role in preserving tissue homeostasis and in directing interstitial capillary filtrate back to the bloodstream. ALPA lymphatic endothelium differs from the endothelia of conduction and flowing vessels (precollectors, prelymph nodal and postlymph nodal collectors, main trunks), since it presents a discontinuous basement membrane, which is often absent, and lacks pores and fenestrations. The mesenchymal origin of the ALPA lymphatic vessel, morphological and ultrastructural aspects, intrinsic contractile properties, the presence of valves, innervation, and specific lymphatic markers that reliably distinguish it from blood capillaries are studied. Furthermore, its role in lymph formation through different mechanisms (hydrostatic pressure and colloidal osmotic-reticular mechanisms, vesicular pathway, and intraendothelial channel) is investigated. We have studied morphological and biomolecular mechanisms that control the transendothelial migration, from the extracellular interstitial matrix into the lumen of the lymphatic vessel, of cells involved in immune response and resistance (lymphocyte recirculation, etc.) and in the tumoral metastatic process via the lymphatic system. Finally, future research prospects, clinical implications, and therapeutic strategies are considered.
Collapse
Affiliation(s)
- Giacomo Azzali
- Section of Human Anatomy, Department of Human Anatomy, Pharmacology and Forensic Medicine, Faculty of Medicine, University of Parma, 43100 Parma, Italy
| |
Collapse
|